News
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...
15h
Zacks Investment Research on MSNCI's Unit Unveils Offering to Expand Access to GLP-1 MedicationsThe health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results